AnaptysBio, Inc.
ANABHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeAnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company carries a $1.66B market cap, placing it firmly in the small-cap category. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
Market Cap
$1.66B
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
9.78
EPS (TTM)
$-1.01
EPS (Fwd)
$5.83
ROE
-114.5%
ROA
6.8%
Cash
$286.5M
Total Debt
$277.4M
Free CF
$8.3M
52W Change
284.8%
Annual Financials
Cash vs Debt
AnaptysBio, Inc. holds $286.5M in cash against $277.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $8.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -114.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $63.2M (2021) to $234.6M (2025), reflecting a 271% increase over the period.
With a beta below 0.7, AnaptysBio, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AnaptysBio, Inc. and its sector.